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 It is no secret that modern medicine has improved people’s lives in virtually every are of healthcare. 
What is also not a secret is how expensive it is. . Not only does the average American spend roughly $5000 on 
healthcare, they also spend roughly $1200 on pharmaceuticals. The candidates gunning for the U.S. presiden-
cy often bring up the topic of rising pharmaceuticals and what they would do to change it. Medical services 
and products as a whole are of concern for virtually all Americans, and many of them are considered over-
priced. The development of these products isn’t cheap, and it needs funding. On the other hand, citizens would 
rather spend that $1200 on other commodities.  Looking at the path of funding for pharmaceuticals and bio-
medical research as a whole can help people understand why.  
 
 Let’s take a quick look at biomedical research as a whole. Though biomedical research in the United 
States is funded through multiple channels, the largest funder of federal research is the National Institutes of 
Health (NIH). Comprising of 27 institutes and centers in the U.S., it pours over $40 billion into research, 
mainly in the form of grants. These grants are awarded to research institutions, mainly universities and medi-
cal schools, where some of the science is done, and about 10% of funding goes to in-house NIH research. NIH
-funded projects cover a wide range of research areas. Some of their biggest in-house projects include cancer 
research; the National Cancer Institutes budget was $5.098 billion. What’s interesting, however, is that this 
number (just over $40 billion) has remained relatively stagnant over the past two decades and has failed to 
keep up with inflation. As a result, less and less projects are being funded - approximately one in five and less 
research is able to be done.  
 
 Pharmaceutical research, on the other hand, is often done by private firms. These firms both raise mon-
ey and perform the resulting research. For example, The Pharmaceutical Research and Manufacturers of 
America (PhRMA) report that $97 billion was spent in 2017 by biopharmaceutical companies on research and 
development (R&D). This industry alone, then, spends more than double the NIH’s research funding on their 
projects. 
 
 These two areas of healthcare are different in several ways, mainly that pharmaceuticals offer one 
product - drugs - while biomedical firms and institutes offer a variety of services. However, there is another 
key distinction:government institutes like the NIH are, well, publically funded, while private institutes like 
Novartis and Pfizer are for-profit. As much as these firms claim they are trying to save lives, at the end of the 
day they are also trying to maximize their profits and will sell their products at the price the market can bear. 
Unlike the NIH, private firms gather their research funds from their profits, meaning they can only produce 
beneficial drugs as long as they are making a profit. When that stops happening, they either raise prices or 
look for another way to make money.  
 
 The path for funding for biomedical research and pharmaceutical development is a complicated one. It 
has clear advantages: institutions across the country are diligently working to produce innovations, improve-
ments, and efficiencies in the world of medicine. Funding a large number of research programs also results in 
a large number of different and varying ideas. The path isn’t perfect, though. A shrinking NIH budget and in-
creasing pharmaceutical company profits paired with increasing pharmaceutical drug costs are concerning 
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